TY - JOUR
T1 - What's new in the medical management of pediatric epilepsy?
AU - Wirrell, Elaine C.
PY - 2012/11
Y1 - 2012/11
N2 - Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20% will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.
AB - Epilepsy affects approximately 45 per 100,000 children per year. While many cases respond favorably to antiepileptic therapy, approximately 20% will prove to be medically intractable. This paper reviews some of the recently identified important metabolic and autoimmune etiologies for which there are specific therapies. Additionally, newer antiepileptic medications, including rufinamide, lacosamide, retigabine, eslicarbazepine and brivaracetam and newer dietary options, including the modified Atkins diet and low-glycemic index diet are discussed.
UR - http://www.scopus.com/inward/record.url?scp=84879913737&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84879913737&partnerID=8YFLogxK
U2 - 10.1017/s0317167100018151
DO - 10.1017/s0317167100018151
M3 - Article
AN - SCOPUS:84879913737
SN - 0317-1671
VL - 39
SP - S30-S34
JO - Canadian Journal of Neurological Sciences
JF - Canadian Journal of Neurological Sciences
IS - 6 SUPPL.6
ER -